||This article's lead section may not adequately summarize key points of its contents. (August 2013)|
|Classification and external resources|
Classification and Pathogenesis
There are two types: congenital and acquired. Acquired cholesteatomas, which are more common, can be caused by pathological alteration of the ear drum leading to accumulation of keratin within the middle ear.
Less commonly the disease may be a developmental abnormality, when it grows from birth behind the ear drum, in the form of a keratin-filled cyst.
Keratin-filled cysts that grow medial to the tympanic membrane result either from birth abnormality, trauma or metaplasia. If they fulfill the following criteria they are considered to be congenital:
- mass medial to the tympanic membrane
- normal tympanic membrane
- no previous history of ear discharge, perforation or ear surgery
Congenital cholesteatomas are more often found in the anterior aspect of the ear drum, and a vestigial structure, the epidermoid formation, from which congenital cholesteatoma may originate, has been identified in this area.
More commonly, keratin accumulates in a pouch of tympanic membrane which extends into the middle ear space. This abnormal folding or 'retraction' of the tympanic membrane arises in one of the following ways:
- Wittmaack's theory : Invagination of tympanic membrane from the attic or posterosuperior part of pars tensa in the form of retraction pockets lead to the formation of cholesteatoma.
- Ruedi's theory : The basal cells of germinal layer of skin proliferate under the influence of infection and lay down keratinising squamous epithelium.
- Habermann's theory: The epithelium from the meatus or outer drum surface grows into the middle ear through a pre-existing perforation and form cholesteatoma.
Cholesteatoma affects all age groups, from infants through to the elderly. The peak incidence occurs in the second decade.
The majority (98%) of patients with cholesteatoma have ear discharge or hearing loss or both in the affected ear.
Other more common conditions, such as otitis externa may also present with these symptoms, but cholesteatoma is much more serious and should not be overlooked. If a patient presents to a doctor with ear discharge and hearing loss, the doctor should consider the patient to have cholesteatoma until the disease is definitely excluded.
Other less common symptoms (all less than 15%) of cholesteatoma may include: pain, balance disruption, tinnitus, ear ache, headaches and bleeding from the ear. There can also be facial nerve weakness. Balance symptoms in the presence of a cholesteatoma raises the possibility that the cholesteatoma is eroding the balance organs, which form part of the inner ear.
On initial inspection, an ear canal full of discharge may be all that is visible. Until the doctor has cleaned the ear and inspected the entire tympanic membrane, cholesteatoma cannot be either confirmed or excluded.
Once the debris is cleared, cholesteatoma can give rise to a number of appearances. If there is significant inflammation, the tympanic membrane may be partially obscured by an aural polyp. If there is less inflammation, the cholesteatoma may present the appearance of 'semolina' discharging from a defect in the tympanic membrane. The posterior and superior parts of the tympanic membrane are most commonly affected. If the cholesteatoma has been dry, the cholesteatoma may present the appearance of 'wax over the attic'. The attic is just above the ear drum.
The patient may commonly also have clinical signs of conductive hearing loss. Less frequently, there may be signs of imbalance or facial weakness.
If untreated, a cholesteatoma can eat into the three small bones located in the middle ear (the malleus, incus and stapes, collectively called ossicles), which can result in nerve deterioration, deafness, imbalance and vertigo. It can also affect and erode, through the enzymes it produces, the thin bone structure that isolates the top of the ear from the brain, as well as lay the covering of the brain open to infection with serious complications (rarely even death due to brain abscess and septicemia).
Both the acquired as well as the congenital types of the disease can affect the facial nerve that extends from the brain to the face and passes through the inner and middle ear and leaves at the anterior tip of the mastoid bone, and then rises to the front of the ear and extends into the upper and lower face.
Cholesteatoma is a persistent disease. Once the diagnosis of cholesteatoma is made in a patient who can tolerate a general anesthetic, the standard treatment is to surgically remove the growth.
General aims of treatment
The challenge of cholesteatoma surgery is to permanently remove the cholesteatoma whilst retaining or reconstructing the normal functions of the structures housed within the temporal bone.
The general objective of cholesteatoma surgery has two parts. It is both directed against the underlying pathology and directed towards maintaining the normal functions of the temporal bone. These aims are conflicting and this makes cholesteatoma surgery extremely challenging.
Sometimes, the situation results in a clash of surgical aims. The need to fully remove a progressive disease like cholesteatoma is the surgeon's first priority. Preservation of hearing is secondary to this primary aim. If the disease can be removed easily so that there is no increased risk of residual disease, then the ossicles may be preserved. If the disease is difficult to remove, so that there is an increased risk of residual disease, then removal of involved ossicles in order to fully clear cholesteatoma has generally been regarded as necessary and reasonable.
In other words, the aims of cholesteatoma treatment form a hierarchy. The paramount objective is the complete removal of cholesteatoma. The remaining objectives, such as hearing preservation, are subordinate to the need for complete removal of cholesteatoma. This hierarchy of aims has led to the development of a wide range of strategies for the treatment of cholesteatoma.
The variation in technique in cholesteatoma surgery results from each surgeons' judgment whether to retain or remove certain structures housed within the temporal bone in order to facilitate the removal of cholesteatoma. These structures are the posterior ear canal wall and the ossicles.
Removal of the canal wall facilitates the complete clearance of cholesteatoma from the temporal bone in three ways:
- it removes a large surface onto which cholesteatoma may be adherent;
- it removes a barrier behind which the cholesteatoma may be hidden;
- it removes an impediment to the introduction of instruments used for the removal of cholesteatoma.
Thus removal of the canal wall provides one of the most effective strategies for achieving the primary aim of cholesteatoma surgery, the complete removal of cholesteatoma. However, there is a trade-off, since the functional impact of canal wall removal, is also important.
The removal of the ear canal wall results in:
- a space, the "mastoid cavity", which is less likely than the original ear canal to resist infection;
- exposure of the ossicles, which may allow the subsequent formation of a new cholesteatoma deep to the ossicles. To prevent this, these ossicles must be removed, which may diminish the patient's hearing.
The formation of a mastoid cavity by removal of the canal wall is the simplest and most effective procedure for facilitating the removal of cholesteatoma, but may bestow the most lasting infirmity due to loss of ear function upon the patient treated in this way.
The following strategies are employed to mitigate the effects of canal wall removal:
- careful design and construction of the mastoid cavity. This is essential for the health and integrity of the protective sheet of migrating, keratising epithelium which lines the distorted ear canal. This requires the surgeon to saucerise the cavity. A high facial ridge and an inappropriately small cartilaginous meatus are obstructions to epithelial migration and are particularly high risk factors for failure of the self-cleaning mechanism of the external ear.
- partial obliteration of the mastoid cavity. This can be performed using a wide range of materials. Many of these resorb in time, which means that the long term results of such surgery are poorer than the short term results.
- reconstruction of the ear canal wall. Canal wall reconstruction has been performed using ear canal skin alone, fascia, cartilage, titanium as well as by replacing the original intact wall. If the reconstruction is poorly performed, it may result in a high rate of recurrent cholesteatoma.
- preservation of the ear canal wall. If poorly performed, it may result in a high rate of both residual and recurrent cholesteatoma.
- reconstruction of the chain of hearing bones.
Clearly, preservation and restoration of ear function at the same time as total removal of cholesteatoma requires a high level of surgical expertise.
It is important that the patient attend periodic follow-up checks, because even after careful microscopic surgical removal, cholesteatomas may recur. Such recurrence may arise many years, or even decades, after treatment.
A residual cholesteatoma may develop if the initial surgery failed to completely remove the original; residual cholesteatomas typically become evident within the first few years after the initial surgery.
A recurrent cholesteatoma is a new cholesteatoma that develops when the underlying causes of the initial cholesteatoma are still present. Such causes can include, for example, poor eustachian tube function, which results in retraction of the ear drum, and failure of the normal outward migration of skin.
In a retrospective study of 345 patients with middle ear cholesteatoma operated on by the same surgeon, the overall 5-year recurrence rate was 11.8%. In a different study with a mean follow-up period of 7.3 years, the recurrence rate was 12.3%, with the recurrence rate being higher in children than in adults.
- Derlacki EL, Clemis JD (1965). "Congenital cholesteatoma of the middle ear and mastoid". Annals of Otology, Rhinology, and Laryngology 74 (3): 706–727. PMID 5846535.
- Michaels L (1988). "Origin of congenital cholesteatoma from a normally occurring epidermoid rest in the developing middle ear". Int J Pediatr Otorhinolaryngol 15 (1): 51–65. doi:10.1016/0165-5876(88)90050-X. PMID 3286554.
- "Chronic suppurative otitis media". ENT. Retrieved 12 January 2013.
- Rueedi L (1959). "Cholesteatoma formation in the middle ear in animal experiments". Acta Oto-Laryngologica 50 (3–4): 233–242. doi:10.3109/00016485909129191. PMID 13660782.
- Haberman J (1888). "Zur Entstehung des Cholesteatoms des Mittelohrs". Archiv fuer Ohrenheilkunde 27: 43–51.
- Sade, J; Babiacki, A; Pinkus, G (1983). "The metaplastic and congenital origin of choesteatoma". Acta Otolaryngologica 96 (1–2): 119–129. doi:10.3109/00016488309132882. PMID 6193677.
- Harker LA (1977). Cholesteatoma: an incidence study in Cholesteatoma First International Conference. Birmingham, Alabama, USA: Aesculapius Publishing Company. pp. 308–309. ISBN 0-912684-11-9.
- Wormald P,J Nilssen EL (1998). "The facial ridge and the discharging mastoid cavity". Annals of Otology, Rhinology, and Laryngology 108 (1): 92–96. PMID 9432074.
- Black B (1995). "Mastoidectomy elimination". Laryngoscope 105 (12 pt 2 Suppl 76): 1–30. doi:10.1288/00005537-199512000-00023. PMID 7500804.
- Deveze A et al (2010). "Rehabilitation of canal wall down mastoidectomy using a titanium ear canal implant". Otol Neurotol 31 (2): 220–224. doi:10.1097/MAO.0b013e3181c9960d. PMID 20009781.
- Jansen C (1968). "The combined approach for tympanoplasty (report on 10 years' experience)". J Laryngol Otoll 82 (9): 779–793. doi:10.1017/S0022215100069462. PMID 4878658.
- Austin DF (1971). "Ossicular reconstruction". Archives of Otolaryngol 94 (6): 525–535. doi:10.1001/archotol.1971.00770070825007. PMID 5129224.
- Fairley, James (7 November 2010). "Cholesteatoma and mastoid surgery". entkent.com. Retrieved 29 December 2012.
- Mishiro, Y.; Sakagami, M.; Kitahara, T.; Kondoh, K.; Okumura, S. (September 2008). "The investigation of the recurrence rate of cholesteatoma using Kaplan-Meier survival analysis". Otology & Neurotology (American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology) 29 (6): 803–6. doi:10.1097/MAO.0b013e318181337f. PMID 18636031.
- Vartiainen, Eero (1995). "Factors associated with recurrence of cholesteatoma". The Journal of Laryngology & Otology 109 (7). doi:10.1017/S0022215100130804.
|Wikimedia Commons has media related to Cholesteatoma.|